New Data on BioLineRx BL-7040 - Analyst Blog
27 Novembre 2013 - 11:05PM
Zacks
BioLineRx (BLRX) announced new data from a
phase IIa study on its pipeline candidate BL-7040. BioLineRx is
developing BL-7040 for the treatment of inflammatory bowel disease
(IBD). Results revealed significant improvement in disease
measurements in biopsies taken from IBD patients treated with
BL-7040. The histological and biochemical analyses of inflammation
indicators back the initial positive results of the study, reported
in April 2013. The initial results revealed that BL-7040 was safe
and effective in treating patients suffering from ulcerative
colitis which is a form of IBD.
In the phase IIa study, Biopsies taken from participants before
and after treatment were collected and randomly assigned to either
a histological evaluation or to an assessment for levels of
cytokines, considered as pro-inflammatory bio-markers. Histological
evaluation in patients treated with BL-7040 revealed significant
reduction in neutrophil levels.
The level of the pro-inflammatory cytokine - interleukin 6
(IL-6) is an additional measure of IBD severity. Significant
reduction was also seen in IL-6 in patients treated with BL-7040.
Data also showed clinical improvement in patients with reduced
cytokine levels.
We note that in Jun 2011, BioLineRx entered into a licensing
agreement with Yissum Research Development Company of the Hebrew
University of Jerusalem Ltd. for BL-7040.
BioLineRx mentioned in its press release that sales generated
from existing IBD drugs in the U.S. were $5.6 billion in 2012.
Companies like Johnson & Johnson (JNJ) and
Shire (SHPG) also have a presence in the IBD
market.
BioLineRx, a biopharmaceutical company, carries a Zacks Rank #4
(Sell). Investors interested in the biopharmaceutical industry may
consider Actelion Ltd. (ALIOF) which carries a
Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
BIOLINE RX LTD (BLRX): Get Free Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(USOTC:ALIOF)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(USOTC:ALIOF)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (OTCMarkets): 0 recent articles
Plus d'articles sur Actelion Ltd. (PC)